High Hope Pharmaceutical Company adopts the group standard of "Guidelines for Sustainable Development of International Supply Chain in the Pharmaceutical Industry"

On the afternoon of June 23rd, the 14th International Development Conference of the Pharmaceutical Industry, jointly organized by the China Chamber of Commerce for Import and Export of Medicines and Health Products and Informa Markets, was successfully held in Shanghai. At the meeting, the group standard "Guidelines for Sustainable Development of International Supply Chain in the Pharmaceutical Industry" was released. High Hope   Pharmaceutical Company, a subsidiary of Jiangsu SOHO   Holdings Group, has been audited and certified by a third-party organization, Shenzhen Tianxiang Quality Technology Service Co., Ltd., and has become one of the first enterprises to meet this standard.

On June 25th, Wang Maochun, Vice President of the China Chamber of Commerce for Import and Export of Medicines and Health Products, issued a certification certificate to High Hope   Pharmaceutical Company at the 23rd CPHI China 2025, stating that the company has achieved standardized, systematic, and digital operational management goals in multiple dimensions such as business management structure, quality system assurance, and labor norms.

The "Guidelines for Sustainable Development of International Supply Chain in the Pharmaceutical Industry", as the first group standard in the pharmaceutical industry to focus on sustainable development of international supply chain, has constructed a four-dimensional framework covering "governance system, social responsibility, environmental protection, and quality and safety", achieving three major breakthroughs: first, deep compatibility with international rules; second, seamless connection with the EU's "Sustainable Product Eco design Regulations"; third, close integration with more than 30 international standards such as the World Health Organization (WHO) and the International Conference on Harmonisation of Pharmaceutical Registration Technologies for Human Use (ICH). The Development Guidelines evaluated more than 10 pharmaceutical companies and announced the list of companies that passed the evaluation to overseas buyers during the exhibition, establishing a model of green pharmaceutical supply chain in China. It will tailor a sustainable development path for the internationalization of China's pharmaceutical industry and promote the integration of Chinese intelligence into the global health governance system.

High Hope   Pharmaceutical Company will take this opportunity to further promote the upgrading of its comprehensive governance ability, resource integration ability, and business innovation ability, continuously focus on the construction of its main business in the pharmaceutical field, and continuously enhance its core competitiveness.